EP 3775267 A4 20220518 - NOVEL ANGIOPOIETIN 2, VEGF DUAL ANTAGONISTS
Title (en)
NOVEL ANGIOPOIETIN 2, VEGF DUAL ANTAGONISTS
Title (de)
NEUARTIGE ANGIOPOIETIN-2, VEGF-DUAL-ANTAGONISTEN
Title (fr)
NOUVEAUX ANTAGONISTES DOUBLES DE VEGF ET DE L'ANGIOPOÏÉTINE 2
Publication
Application
Priority
- US 201862655436 P 20180410
- US 2019026838 W 20190410
Abstract (en)
[origin: CN112262158A] The present invention relates to fusion molecules and chimeric molecules comprising two components: Ang2 antagonist peptides linked to VEGF binding moieties. Further disclosed are methods of treatingcancer, proliferative retinopathy, neovascular glaucoma, macular edema, wet age-related macular degeneration (wAMD), macular edema after retinal vein occlusion (RVO), diabetic macular edema (DME), ordiabetic retinopathy (DR) in a patient using the chimeric molecules.
IPC 8 full level
C07K 16/22 (2006.01); A61K 39/00 (2006.01); A61P 27/02 (2006.01)
CPC (source: EP)
A61P 27/02 (2017.12); C07K 16/22 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/622 (2013.01); C07K 2317/76 (2013.01); C07K 2319/00 (2013.01); C07K 2319/32 (2013.01)
Citation (search report)
- [X] WO 2017197199 A1 20171116 - ASKGENE PHARMA INC [US], et al
- [A] WO 2016073915 A1 20160512 - NOVARTIS AG [CH], et al
- [A] SCHAUWVLIEGHE A. M. E. ET AL: "Comparing the Effectiveness of Bevacizumab to Ranibizumab in Patients with Exudative Age-Related Macular Degeneration. The BRAMD Study", PLOS ONE, vol. 11, no. 5, 1 May 2016 (2016-05-01), pages e0153052, XP055909670, DOI: 10.1371/journal.pone.0153052
- See references of WO 2019200006A2
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
DOCDB simple family (publication)
WO 2019200006 A2 20191017; CN 112262158 A 20210122; EP 3775267 A2 20210217; EP 3775267 A4 20220518
DOCDB simple family (application)
US 2019026838 W 20190410; CN 201980024414 A 20190410; EP 19784270 A 20190410